ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BIIB095
Previous Study | Return to List | Next Study

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03454126
Recruitment Status : Recruiting
First Posted : March 5, 2018
Last Update Posted : September 19, 2018
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:
The primary objective of the study is to evaluate the safety and tolerability of single- and multiple-ascending oral doses of BIIB095 in healthy participants. The secondary objectives are to characterize the single- and multiple-oral-dose PK of BIIB095 in healthy participants and to investigate the effect of food on the single-oral-dose PK of BIIB095 in healthy participants.

Condition or disease Intervention/treatment Phase
Chronic Pain Including Neuropathic Pain Drug: BIIB095 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Subjects
Actual Study Start Date : March 29, 2018
Estimated Primary Completion Date : January 28, 2019
Estimated Study Completion Date : January 28, 2019

Arm Intervention/treatment
Experimental: Cohort 1: BIIB095 5 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 2: BIIB095 25 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 3: BIIB095 100 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 4 (Fasted): BIIB095 200 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 4 (Fed): BIIB095 200 mg
After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 5: BIIB095 400 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 6: BIIB095 600 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 7: BIIB095 50 mg BID
Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 8: BIIB095 100 mg BID
Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 9: BIIB095 200 mg BID
Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Cohort 10: BIIB095 300 mg BID
Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.




Primary Outcome Measures :
  1. Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]

    An SAE is any untoward medical occurrence that at any dose:

    Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event


  2. Percentage of Participants with Adverse Events (AEs) [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

  3. Percentage of Participants with Clinically Significant Abnormalities in Clinical Laboratory Assessments [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]
  4. Percentage of Participants with Clinically Significant Abnormalities in Vital Signs [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]
  5. Percentage of Participants with Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]
  6. Percentage of Participants with Clinically Significant Abnormalities in Physical Examinations [ Time Frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10) ]

Secondary Outcome Measures :
  1. Area Under the Concentration-Time Curve (AUC) from Time Zero to the Time of the Last Measurable Concentration (AUClast) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  2. AUC from Time Zero Extrapolated to Infinity (AUC∞) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  3. AUC Within a Dosing Interval (AUCtau) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  4. Maximum Observed Concentration (Cmax) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  5. Trough Concentration (Ctrough) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  6. Time to Cmax (Tmax) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  7. Terminal Elimination Half-Life (t1/2) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  8. Apparent Total Body Clearance (CL/F) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  9. Apparent Volume of Distribution (Vz/F) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  10. Accumulation Ratio (AR) [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  11. Amount (Aeu) Excreted in Urine [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.

  12. Percentage (%fe) Excreted in Urine [ Time Frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts ]
    Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Ability of the subject to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.
  • Must have a body mass index between 18 and 30 kg/m2, inclusive.
  • All women of childbearing potential and all men must practice highly effective contraception during the study and for 5 times the half-life or 3 months, whichever is longer, after their last dose of study treatment. In addition, subjects should not donate sperm or eggs during the study and for at least 3 months after their last dose of study treatment.
  • Must be in good health as determined by the Investigator, based on medical history and Screening evaluations.

Key Exclusion Criteria:

  • History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • Significant history of fainting or vaso-vagal attacks, as determined by the Investigator.
  • Current condition known to affect cardiac conduction, or a personal or familial history of Brugada syndrome.
  • Congenital nonhemolytic hyperbilirubinemia (Gilbert's syndrome).
  • History or risk of seizures or a history of epilepsy, significant head injury or related neurological disorders (excluding childhood febrile convulsions), as determined by the Investigator.
  • Current enrollment in any other drug, biologic, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days (6 months for biologics) prior to Day -1, or 5 half-lives of the agent, whichever is longer.
  • Exposure to more than 4 experimental chemical entities within 12 months prior to the first dosing day.
  • Breastfeeding, pregnant, or planning to become pregnant during study participation

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03454126


Contacts
Contact: US Biogen Clinical Trial Center 866-633-4636 clinicaltrials@biogen.com
Contact: Global Biogen Clinical Trial Center clinicaltrials@biogen.com

Locations
United Kingdom
Research Site Recruiting
Leeds, United Kingdom, LS2 9LH
Hammersmith Medicines Research Not yet recruiting
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Biogen
Investigators
Study Director: Medical Director Biogen

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT03454126     History of Changes
Other Study ID Numbers: 255HV101
2017-003982-90 ( EudraCT Number )
First Posted: March 5, 2018    Key Record Dates
Last Update Posted: September 19, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Biogen:
Chronic pain
Neuropathic pain
Neuralgia
Healthy volunteers

Additional relevant MeSH terms:
Chronic Pain
Neuralgia
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Peripheral Nervous System Diseases
Neuromuscular Diseases